Zoloft

Pfizer Inc is a pharmaceutical company based in New York, NY, specializing in the research, development, and manufacturing of a wide range of medications and vaccines. With a focus on improving global health, Pfizer Inc is dedicated to providing innovative solutions to address various medical needs and enhance patient outcomes. Generated from their business information

AnHeart Therapeutics is a clinical-stage biopharmaceutical company based in New York, NY, dedicated to developing innovative precision therapies for individuals with cancer. Their pipeline includes promising clinical stage assets such as Taletrectinib, a ROS1 inhibitor for non-small cell lung cancer, Safusidenib, an mIDH1 inhibitor for glioma and other tumors, and AB-329, an axl inhibitor for overcoming checkpoint inhibitor resistance in various tumors. With a mission to advance precision oncology therapeutics, AnHeart Therapeutics collaborates with leading organizations like Innovent and Foundation Medicine to develop companion diagnostics and gain regulatory approvals for their novel therapies. Their commitment to scientific excellence and strategic partnerships positions them at the forefront of the fight against cancer.Generated from the website

Q BioMed Inc. is a biotech acceleration and commercialization company based in New York, NY. They specialize in acquiring, developing, and financing undervalued biomedical assets in various therapeutic areas, with a focus on the biotechnology and healthcare sectors. Their strategic approach involves minimizing risk, sharing success, and accelerating technologies from incubation to monetization, ultimately aiming to provide public market access for private company assets. With expertise in business product development and capital formation, Q BioMed Inc. aims to bridge the gap for biomedical start-ups lacking capital and resources to transition from incubation to development and beyond. Their strategy revolves around maximizing risk-adjusted returns by focusing on value-driven assets, ranging from early-stage to near-revenue businesses, where technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.Generated from the website